XML 42 R27.htm IDEA: XBRL DOCUMENT
v3.25.1

REVENUE (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Revenue | Disaggregation of total revenues by nature is as follows:
| Three Months Ended March 31, |  |
(in thousands) | 2025 |  | 2024 |  |  |  |
Product sales, net | $ | 67,814 |  |  | $ | 43,512 |  |  |  |  |
Licensing revenue | 5,020 |  |  | 17 |  |  |  |  |
Non-cash royalty revenue related to the sale of future royalties | 1,026 |  |  | 368 |  |  |  |  |
Product supply revenue | 254 |  |  | 2,126 |  |  |  |  |
Total revenues | $ | 74,114 |  |  | $ | 46,023 |  |  |  |  |
Total product sales, net was as follows:
| Three Months Ended March 31, |  |
(in thousands) | 2025 |  | 2024 |  |  |  |
Product sales, net |  |  |  |  |  |  |
IBSRELA | $ | 44,403 |  |  | $ | 28,361 |  |  |  |  |
XPHOZAH | 23,411 |  |  | 15,151 |  |  |  |  |
Total product sales, net | $ | 67,814 |  |  | $ | 43,512 |  |  |  |  |
The following table summarizes total revenues by collaboration partner:
| Three Months Ended March 31, |  |
(in thousands) | 2025 |  | 2024 |  |  |  |
Licensing revenue |  |  |  |  |  |  |
Fosun Pharma | $ | 5,000 |  |  | $ | — |  |  |  |  |
Knight | 20 |  |  | 17 |  |  |  |  |
Total licensing revenue | $ | 5,020 |  |  | $ | 17 |  |  |  |  |
Product supply revenue |  |  |  |  |  |  |
Kyowa Kirin | — |  |  | 2,126 |  |  |  |  |
Knight | 254 |  |  | — |  |  |  |  |
Total supply revenue | $ | 254 |  |  | $ | 2,126 |  |  |  |  |
Non-cash royalty revenue related to the sale of future royalties |  |  |  |  |  |  |
Kyowa Kirin | $ | 1,026 |  |  | $ | 368 |  |  |  |  |
Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net | Gross product sales from Customers accounting for more than 10% of total revenues were as follows:
| Three Months Ended March 31, |  |
| 2025 |  | 2024 |  |  |  |
Customers(1) |  |  |  |  |  |  |
BioRidge Pharma, LLC | 63.8 | % |  | 64.6 | % |  |  |  |
Cardinal Health | 22.2 | % |  | 19.2 | % |  |  |  |
Cencora (formerly AmerisourceBergen Drug Corporation) | 18.2 | % |  | 21.6 | % |  |  |  |
McKesson Corporation | 16.9 | % |  | 16.0 | % |  |  |  |
(1)The total of the above percentages exceeds 100% as the numerators used in the calculations represent gross product sales for each Customer, as opposed to product sales, net as presented in our condensed statements of operations and comprehensive loss.
Schedule of Chargebacks, Discounts and Reserve Balances | The activities and ending reserve balances for each significant category of GTN adjustments on product sales, net, which constitute variable consideration, were as follows:
(in thousands) | Discounts and Chargebacks |  | Rebates, Wholesaler and GPO Fees |  | Copay Assistance and Returns |  | Total
Balance as of December 31, 2024 | $ | 1,643 |  |  | $ | 14,475 |  |  | $ | 11,170 |  |  | $ | 27,288 |
Provisions(1) | 4,143 |  |  | 18,835 |  |  | 5,940 |  |  | 28,918 |
Credits/payments | (4,681) |  |  | (18,405) |  |  | (8,334) |  |  | (31,420) |
Balance as of March 31, 2025 | $ | 1,105 |  |  | $ | 14,905 |  |  | $ | 8,776 |  |  | $ | 24,786 |
(1) Provisions included approximately $3.8 million of favorable adjustment resulting from changes in prior periods’ estimated product returns for XPHOZAH.

X
- Definition Schedule Of Gross To Net Sales Accruals + References No definition available. + Details
Name: | ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock
Namespace Prefix: | ardx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration